CN Patent

CN110227067B — 一种盐酸普拉克索缓释片及其制备方法

Assigned to Hybio Pharmaceutical Co Ltd · Expires 2021-03-02 · 5y expired

What this patent protects

一种普拉克索缓释片，其由以下组分制成，且各组分之和为100％，其中，盐酸普拉克索0.12％‑0.45％、填充剂50％‑60％、缓释基质25％‑35％、粘合剂8％‑12％、助流剂0.3％‑3％、润滑剂0.1％‑1.0％，缓释基质为Eudragit RD、羟丙甲纤维素K100M或其组合，优选为Eudragit RD和羟丙甲纤维素K100M的组合；助流剂和润滑剂的比例为助流剂：润滑剂＝0.5‑10，优选为0.6‑8。

USPTO Abstract

一种普拉克索缓释片，其由以下组分制成，且各组分之和为100％，其中，盐酸普拉克索0.12％‑0.45％、填充剂50％‑60％、缓释基质25％‑35％、粘合剂8％‑12％、助流剂0.3％‑3％、润滑剂0.1％‑1.0％，缓释基质为Eudragit RD、羟丙甲纤维素K100M或其组合，优选为Eudragit RD和羟丙甲纤维素K100M的组合；助流剂和润滑剂的比例为助流剂：润滑剂＝0.5‑10，优选为0.6‑8。

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: CN110227067B
Jurisdiction: CN
Classification: —
Expires: 2021-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Hybio Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.